Integrate current evidence-based interventions for MacTel into clinical practice to optimize disease outcomes. This activity ...

Clinically relevant and statistically significant primary results with the NT-501 implant demonstrated change in the rate of progression of disease in Macular telangiectasia type 2 (MacTel) patients ...

Please provide your email address to receive an email when new articles are posted on . Patients with smaller baseline ellipsoid zone area loss and patients with diabetes had better response. Earlier ...

John A. Moran Eye Center physician-researcher Paul S. Bernstein, MD, PhD, and his patients at the University of Utah played a key role in the recent discovery of the first genetic cause for a rare eye ...

SAN FRANCISCO -- Photoreceptor loss in macular telangiectasia (MacTel) type 2 decreased by as much as 56% with a cellular therapy that produces a neurotrophic factor, two sham-controlled trials showed ...

MacTel type 2 is a rare retinal condition causing central vision loss, with no current treatments available. NT-501, a potential treatment for MacTel, has its FDA decision delayed to March 18, 2025, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. KOLOA, Hawaii — In this Healio Video Perspective from ...

Researchers have identified an additional seven regions in the human genome that increase the risk of developing MacTel (macular telangiectasia type 2), including a rare DNA mutation in the PHGDH gene ...

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, announces that the U.S. Food and Drug Administration (FDA), ...